ClinicalTrials.gg
RecruitingNCT07879170Updated Oct 16, 2026

A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants

A Phase 1 interventional study of EPX-100 and EPX-100-Matching Placebo in Healthy Participants, sponsored by Epygenix. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Epygenix · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A study to evaluate the safety and tolerability of single and multiple ascending doses of EPX-100 in healthy adult participants.

Read the detailed description

This is a two-part study. Part 1 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of EPX-100 following single ascending doses (SAD). Part 2 is a randomized, double-blind, placebo- and positive-controlled (active comparator) study to evaluate the safety, tolerability, and PK of EPX-100 following multiple ascending doses (MAD). In addition, cardiac liability will be evaluated in each cohort.

02

Conditions studied

  • Healthy Participants

Keywords

  • Multiple Ascending Dose
  • Single Ascending Dose
03

In context

Lead sponsor

Epygenix is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Continuous nonsmoker who has not used nicotine- or tobacco-containing products for at least 3 months prior to (first) dosing.
  • ≥18.0 and ≤32.0 kilograms per square meter(kg/m\^2) at the Screening visit (defined as within 28 days prior to dosing).
  • Medically healthy with no medical history, physical examination findings, clinical laboratory profiles, vital signs, and (ECGs), as deemed by the Principal Investigator (PI) or designee.
  • Part 2 only: No clinically significant history and presence of ECG findings as judged by the PI or designee at the Screening visit and at Check-In.

Exclusion criteria

Exclusion Criteria:

  • History of cholecystectomy.
  • Has a family history of sudden cardiac death, unexplained death, or death from a primary dysrhythmia potentially associated with in any family member.
  • History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
  • History of seizure (excluding simple febrile seizure), epilepsy, severe head injury, multiple sclerosis, or other known neurological conditions that the PI or designee considers to be .
  • History of presence of ventricular dysfunction or risk factors for Torsades de Pointes (e.g., heart failure, cardiomyopathy, family history of Long QT Syndrome or sudden unexpected cardiac death at a young age).
  • Part 2 only: history or presence of sick sinus syndrome, second or third degree atrioventricular block, myocardial infarction, pulmonary congestion, symptomatic or significant cardiac arrhythmia, prolonged QTcF interval, or conduction abnormalities.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Part 1 SAD: EPX-100

    Sequential cohorts of participants will receive a single ascending dose of EPX-100.

    Drug: EPX-100

  • Placebo comparator
    Part 1 SAD: Placebo

    Participants will receive a single dose of EPX-100-matching placebo.

    Drug: EPX-100-Matching Placebo

  • Experimental
    Part 2 MAD: Treatment Arm

    Participants will receive EPX-100 twice daily on Days 1 to 13, and a morning dose of EPX-100 on Day 14. Moxifloxacin-matching placebo will be administrated on Days 1 and 15. Participants will also receive a single dose of EPX-100-matching placebo on the morning of Days -1 and 15.

    Drug: EPX-100 · Drug: EPX-100-Matching Placebo · Drug: Moxifloxacin-Matching Placebo

  • Active comparator
    Part 2 MAD: Control Arm

    Participants will receive moxifloxacin or moxifloxacin-matching placebo on the morning of Day 1 then will cross over to the alternate treatment on the morning of Day 15. EPX-100-matching placebo will be administered twice daily on Days 1 to 13 with a morning dose on Day 14. Participants will also receive a single dose of EPX-100-matching placebo on the morning of Days -1 and 15.

    Drug: EPX-100-Matching Placebo · Drug: Moxifloxacin · Drug: Moxifloxacin-Matching Placebo

Interventions

  • Oral solution

    Also known as: clemizole, clemizole hydrochloride (HCL)

  • DrugEPX-100-Matching Placebo

    Oral Solution

  • Over-encapsulated tablet

  • DrugMoxifloxacin-Matching Placebo

    Capsule

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs) in Part 1 SAD

    Time frame: Part 1 SAD: up to Day 18

  2. Number of Participants with TEAEs in Part 2 MAD

    Time frame: Part 2 MAD: up to Day 31

Secondary outcomes

  1. Area Under the concentration-time curve (AUC), From Time 0 to The Last Observed Nonzero Concentration (AUC0-last) of EPX-100 and Metabolites in Plasma

    Time frame: Part 1 SAD: up to Day 4, Part 2 MAD: up to Day 17

  2. AUC0-last of EPX-100 and Metabolites in Urine

    Time frame: Part 1 SAD: up to Day 4

  3. Maximum Observed Concentration (Cmax) of EPX-100 and Metabolites in Plasma

    Time frame: Part 1 SAD: up to Day 4, Part 2 MAD: up to Day 17

  4. Cmax of EPX-100 and Metabolites in Urine

    Time frame: Part 1 SAD: up to Day 4

  5. Change from Baseline in Electrocardiogram (ECG) QT Interval Corrected According to the Method of Fridericia (QTcF)

    Time frame: Part 2 MAD: Baseline and up to Day 16

07

Study locations

1 of 1 sites recruiting
  • Celerion
    Tempe, Arizona 85283, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 16, 2026
StartActual
Aug 5, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07879170
Lead sponsor
Epygenix
Responsible party
Sponsor
First posted
Oct 16, 2026
Start date
Aug 5, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@harmonybiosciences.com
see email
Robert Faulkner, PhD
study director · Epygenix Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clemizole hydrochloride

Start the discussion